{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:04:49Z","timestamp":1792087489064,"version":"4.4.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,6,12]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Transcription factor KLF2 is a critical determinant of vascular thrombosis. The antithrombotic effect noted with bortezomib is KLF2 dependent.<\/jats:p>","DOI":"10.1182\/blood-2014-01-547448","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T01:48:31Z","timestamp":1398476911000},"page":"3828-3831","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)"],"prefix":"10.1182","volume":"123","author":[{"given":"Lalitha","family":"Nayak","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, and"},{"name":"Harrington Heart and Vascular Institute, Case Cardiovascular Research Institute, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shi","sequence":"additional","affiliation":[{"name":"Harrington Heart and Vascular Institute, Case Cardiovascular Research Institute, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Brandon","family":"Atkins","sequence":"additional","affiliation":[{"name":"Harrington Heart and Vascular Institute, Case Cardiovascular Research Institute, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Lin","sequence":"additional","affiliation":[{"name":"Harrington Heart and Vascular Institute, Case Cardiovascular Research Institute, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin H.","family":"Schmaier","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh K.","family":"Jain","sequence":"additional","affiliation":[{"name":"Harrington Heart and Vascular Institute, Case Cardiovascular Research Institute, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"29","key":"2019111817351847900_B1","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer.","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111817351847900_B2","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111817351847900_B3","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1001\/jama.296.21.2558-c","article-title":"Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.","volume":"296","author":"Bennett","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"2019111817351847900_B4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2009.07803.x","article-title":"Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.","volume":"146","author":"Jagannath","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111817351847900_B5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","article-title":"Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.","volume":"19","author":"Palumbo","year":"2008","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111817351847900_B6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1160\/TH03-11-0707","article-title":"Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats.","volume":"92","author":"Ostrowska","year":"2004","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111817351847900_B7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.thromres.2007.06.013","article-title":"Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.","volume":"121","author":"Avcu","year":"2008","journal-title":"Thromb Res"},{"issue":"6","key":"2019111817351847900_B8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.12522","article-title":"Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.","volume":"93","author":"Zangari","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2019111817351847900_B9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.leukres.2010.08.007","article-title":"Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.","volume":"35","author":"Shen","year":"2011","journal-title":"Leuk Res"},{"issue":"11","key":"2019111817351847900_B10","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1182\/blood-2005-08-3465","article-title":"KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium.","volume":"107","author":"Dekker","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111817351847900_B11","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1152\/physrev.00058.2009","article-title":"Mammalian Kr\u00fcppel-like factors in health and diseases.","volume":"90","author":"McConnell","year":"2010","journal-title":"Physiol Rev"},{"issue":"5334","key":"2019111817351847900_B12","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1126\/science.277.5334.1986","article-title":"LKLF: A transcriptional regulator of single-positive T cell quiescence and survival.","volume":"277","author":"Kuo","year":"1997","journal-title":"Science"},{"issue":"17","key":"2019111817351847900_B13","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1073\/pnas.0508235103","article-title":"Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes.","volume":"103","author":"Das","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111817351847900_B14","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1084\/jem.20031132","article-title":"KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation.","volume":"199","author":"SenBanerjee","year":"2004","journal-title":"J Exp Med"},{"issue":"5","key":"2019111817351847900_B15","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/01.RES.0000159707.05637.a1","article-title":"Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function.","volume":"96","author":"Lin","year":"2005","journal-title":"Circ Res"},{"issue":"5","key":"2019111817351847900_B16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/01.ATV.0000215638.53414.99","article-title":"Kruppel-like factor 2 inhibits protease activated receptor-1 expression and thrombin-mediated endothelial activation.","volume":"26","author":"Lin","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2019111817351847900_B17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.immuni.2011.04.014","article-title":"The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock.","volume":"34","author":"Mahabeleshwar","year":"2011","journal-title":"Immunity"},{"issue":"5","key":"2019111817351847900_B18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.ajpath.2013.01.029","article-title":"Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation.","volume":"182","author":"Nayak","year":"2013","journal-title":"Am J Pathol"},{"issue":"10","key":"2019111817351847900_B19","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1161\/ATVBAHA.109.191957","article-title":"Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Kr\u00fcppel -like transcription factors.","volume":"29","author":"Hiroi","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"2019111817351847900_B20","doi-asserted-by":"crossref","first-page":"H796","DOI":"10.1152\/ajpheart.00712.2012","article-title":"Kruppel-like factor 2 protects against ischemic stroke by regulating endothelial blood brain barrier function.","volume":"304","author":"Shi","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"2019111817351847900_B21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1124\/jpet.104.069229","article-title":"The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.","volume":"311","author":"Nieman","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"20","key":"2019111817351847900_B22","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.2174\/092986708785132852","article-title":"Platelet-monocyte interactions\u2013a dangerous liaison linking thrombosis, inflammation and atherosclerosis.","volume":"15","author":"Seizer","year":"2008","journal-title":"Curr Med Chem"},{"issue":"1","key":"2019111817351847900_B23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1160\/TH05-07-0477","article-title":"Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.","volume":"95","author":"Zhang","year":"2006","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019111817351847900_B24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/STROKEAHA.109.577288","article-title":"Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.","volume":"41","author":"Zhang","year":"2010","journal-title":"Stroke"},{"issue":"12","key":"2019111817351847900_B25","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1172\/JCI66056","article-title":"Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice.","volume":"122","author":"Zhou","year":"2012","journal-title":"J Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/24\/3828\/1377666\/3828.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/24\/3828\/1377666\/3828.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T17:35:34Z","timestamp":1574098534000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/24\/3828\/32991\/The-thromboprotective-effect-of-bortezomib-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,12]]},"references-count":25,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2014,6,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-01-547448","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,12]]}}}